Do COVID-19 Vaccine Manufacturers Worry Over Pricing Language in Contracts?

February 16, 2021

Despite objections by pharmaceutical companies against price regulations, at least three major companies agreed to such terms in the context of COVID-19 vaccine contracts. Although the COVID-19 constitutes an unexpected situation, these contracts set a precedent for future agreements regarding price controls in the United States.

According to Washington University associate law professor Rachel Sachs, “COVID has changed the conventional wisdom around a number of different kinds of policies in the innovation context for new drugs, devices and vaccines. And I wouldn’t be surprised if this was part of a rethink of drug pricing issues as well.” Learn more here.

(Source: Sarah Karlin-Smith, Pink Sheet, Informa Pharma Intelligence, 2/8/21)

Share This Story!